Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-α in subacule sclerosing panencephalitis (SSPE): International multicenter study

Journal of Child Neurology

Volumn 18, Issue 12, 2003, Pages 819-827

  Gascon, Generoso G ^d,e   Anlar, Banu ^a   Güven, Alev ^a   Haspolat, Senay ^a   Köse, Gulsen ^a   Yalaz, Kalbiye ^a   Fojas, Myna ^b   Andong, Susan ^b   Bolanos, Martha ^b   Sosa, Madeline ^b   Udani, Vrajesh ^c   Sanghani, Chaula ^c   Devol, Ed ^e   Al Kurnas, Abdullah ^e   Turgonyi, Eva ^f   Benoit, Kenneth ^g   Dhib Jalbut, Suhayl ^h   Dyken, Paul ^h   Eggenbauer, Heinz ^h   Jovic, Nebosja ^h   Kalmanchey, Rosalia ^h   Kulczyski, Jerzy ^h   Liebert, Uwe ^h   Mehta, Pankaj ^h   Nester, Michael ^h   Nihei, Kenji ^h   Lahorgue, Magda ^h   Philippart, Michel ^h   more..

^a HACETTEPE UNIVERSITY   (Turkey)

^b MAKATI MEDICAL CENTER   (Philippines)

^c P D HINDUJA NATIONAL HOSPITAL   (India)

^d BROWN UNIVERSITY   (United States)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f Newport Pharmaceuticals Ltd   (Ireland)

^g TRINITY COLLEGE DUBLIN   (Ireland)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; IMMUNOGLOBULIN G; MEASLES ANTIBODY; METHISOPRINOL; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; BRAIN BIOPSY; BRAIN DISEASE; BRAIN FUNCTION; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DETERIORATION; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; HYPERPYREXIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEASLES VIRUS; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MORBIDITY; MULTICENTER STUDY; MYOCLONUS SEIZURE; NEUROLOGIC EXAMINATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REGRESSION ANALYSIS; REMISSION; SUBACUTE SCLEROSING PANENCEPHALITIS; TREATMENT OUTCOME;

EID: 9144253159     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380301801201     Document Type: Article

References (19)

1. Dyken PR: Subacute sclerosing panencephalitis: Current status. Neurology Clin 1985;3:179-196.
2. Haslam RHA, McQujillen MP, Clark DB: Amantadine therapy in SSPE. Neurology 1969;19:1080-1085.
3. Robertson WC Jr, Clark DB, Markesbery WR: Review of 39 cases of SSPE: Effect of amantadine on the natural course of the disease. Ann Neurol 1980;8:42-45.
4. Jones CE, Dyken PR, Huttenlocher PR, et al: Inosiplex therapy in SSPE, a multi-centre, non-randomized study in 98 patients. Lancet 1982;i:1034-1037.
5. Fukuyama Y, Nihei I, Matsumoto S, et al, of the Inosiplex-SSPE Research Committee: Clinical effects of MDN-19 (inosiplex) on SSPE: A multi-institutional collective study. Brain Dev 1987:9:270-282.
6. Yalaz K , Anlar B, Öktem F, et al: Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992;42:488-491.
7. Gascon GG, Yamani S, Crowell J, et al: Combined oral Isoprinosine-intraventricular alpha interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993;15:346-355.
8. Panitch HS: Treatment of subacute sclerosing panencephalitis with interferon, in Smith RA (ed): Interferon Treatment of Neurologic Disorders. New York, Marcel Dekker, 1988, 187-207.
9. Durant RH, Dyken PR, Swift A: The influence of inosiplex treatment on the neurological disability of patients with SSPE. J Pediatr 1982;101:288-293.
10. Nester M: Use of a brief assessment exam in a study involving Isoprinosine and alpha interferon treatment of SSPE. J Child Neurol 1996;11:173-180.
11. Oktem F, Nester MJ, Anlar B: Mental assessment in SSPE: Hacettepe Cognitive Short Assessment. J Child Neurol 1997; 11:398-402.
12. Conrad AJ, Chiang EY, Andeen LE, Tourtellotte WW: Quantitation of intrathecal measles virus IgG antibody synthesis rate: SSPE and multiple sclerosis. J Neuroimmunol 1994;54:99-108.
13. Anlar B, Köse G, Gürer Y, et al: Changing epidemiological features of subacute sclerosing panencephalitis. Infection 2001;29:192-195.
14. Hosoya M, Shigeta S, Mori S, et al: High-dose intravenous ribvarin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001;45:943-945.
15. Tomoda A, Shiraishi S, Hosoya M, et al: Combined treatment with interferon-alpha and ribavarin for subacute sclerosing panencephalitis. Pediatr Neurol 2001;24:54-59.
16. Solomon T, Hart CA, Vinjamuri S, et al. Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavarin, and inosiplex. J Child Neurol 2002;17:703-705.
17. Aydin OF, Senbil N, Kuyucu N, Gürer YK: Combined treatment with subcutaneous interferon-alpha, oral Isoprinosine, and lamivudine for subacute sclerosing panencephalitis. J Child Neurol 2003;18:104-108.
18. Brismar J, Gascon G: Neuroimaging of the brain in 52 patients with subacute sclerosing panencephalitis. AJNR Am J Neuroradiol 1996;17:761-772.
19. Anlar B, Saatçi I, Köse G, Yalaz K: MRI findings in subacute sclerosing panencephalitis. Neurology 1996;47:1278-1283.